Abstract
We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n=53), RAEB in transformation (RAEB-T, n=29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n=15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4–19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n=57) or alternative family donor (n=1). Stem cell source was bone marrow (n=69) or peripheral blood (n=28). With a median follow-up of 3.9 years (range 0.1–10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Niemeyer CM, Kratz CP . Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008; 140: 610–624.
Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR . A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106: 1027–1032.
Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA . Pediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758–767.
Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277–282.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues . IARC Press: Lyon, 2008.
Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001; 15: 1713–1720.
Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002; 20: 434–440.
Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8: 844–849.
Munoz A, de Heredia CD, Badell I, Bureo E, Gomez P, Martinez A et al. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol 2009; 26: 345–355.
Parikh SH, Mendizabal A, Martin PL, Prasad VK, Szabolcs P, Driscoll TA et al. Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant 2009; 15: 948–955.
Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004; 33: 805–814.
Cantu RA, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I . Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84: 429–433.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461–466.
Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 456–481.
Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.
Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001–1011.
Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R . Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993; 83: 602–607.
Cox D . Regression models and life tables (with discussion). J Royal Stat Soc B 1972; 34: 187.
Kruskal WH, Wallis WA . Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583–621.
Mann HB, Whitney DR . On a test of whether one or two random variables is stochastically larger than the other. Ann MathStat 1947; 18: 50–60.
Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger SP et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 2005; 35: 143–149.
Woodard P, Barfield R, Hale G, Horwitz E, Leung W, Ribeiro R et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006; 47: 931–935.
Pession A, Rizzari C, Putti MC, Masetti R, Casale F, Fagioli F et al. Results of the AIEOP AML 2002/01 study for treatment of children with acute myeloid leukemia. Blood (ASH Annu Meet Abstr) 2009; 114: 17.
Zecca M, Masetti R, Balduzzi A, Fagioli F, Dini G, Messina C et al. Long-term outcome of children with acute myeloid leukemia in first remission given allogeneic HSCT from a matched family donor after a conditioning regimen comprising busulfan, cyclophosphamide and melphalan. Blood (ASH Annu Meet Abstr) 2009; 114: 2288.
Chan GC, Wang WC, Raimondi SC, Behm FG, Krance RA, Chen G et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia 1997; 11: 206–211.
Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996; 10: 1269–1273.
Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K . Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714–1720.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Strahm, B., Nöllke, P., Zecca, M. et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 25, 455–462 (2011). https://doi.org/10.1038/leu.2010.297
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.297
Keywords
This article is cited by
-
The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
BMC Pediatrics (2022)
-
Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
Bone Marrow Transplantation (2021)
-
Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome
Bone Marrow Transplantation (2021)
-
Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome
Bone Marrow Transplantation (2020)
-
Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial
Leukemia (2020)